Helius Medical Technologies, Inc. (HSDT)

Market Cap	3.39M
Revenue (ttm)	502,000
Net Income (ttm)	-8.86M
Shares Out	3.73M
EPS (ttm)	-4.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121,369,787
Open	1.030
Previous Close	0.452
Day's Range	0.702 - 1.450
52-Week Range	0.373 - 9.500
Beta	1.59
Analysts	Buy
Price Target	24.00 (+2,537.36%)
Earnings Date	Nov 12, 2024

About HSDT

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company’s product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. Heliu...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2014
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: HSDT
• Website: https://heliusmedical.com

Financial Performance

In 2023, HSDT's revenue was $644,000, a decrease of -18.17% compared to the previous year's $787,000. Losses were -$8.85 million, -37.11% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for HSDT stock is "Buy." The 12-month stock price forecast is $24.0, which is an increase of 2,537.36% from the latest price.

Price Target

$24.0

(2,537.36% upside)

Analyst Consensus: Buy